



# LUND UNIVERSITY

## Automated image-based assay for evaluation of HIV neutralization and cell-to-cell fusion inhibition

Sheik-Khalil, Enas; Bray, Mark-Anthony; Özkaya Sahin, Gülsen; Scarlatti, Gabriella; Jansson, Marianne; Carpenter, Anne E.; Fenyö, Eva Maria

*Published in:*  
BMC Infectious Diseases

*DOI:*  
[10.1186/1471-2334-14-472](https://doi.org/10.1186/1471-2334-14-472)

2014

[Link to publication](#)

*Citation for published version (APA):*  
Sheik-Khalil, E., Bray, M.-A., Özkaya Sahin, G., Scarlatti, G., Jansson, M., Carpenter, A. E., & Fenyö, E. M. (2014). Automated image-based assay for evaluation of HIV neutralization and cell-to-cell fusion inhibition. *BMC Infectious Diseases*, 14, Article 472. <https://doi.org/10.1186/1471-2334-14-472>

*Total number of authors:*  
7

### General rights

Unless other specific re-use rights are stated the following general rights apply:  
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

Read more about Creative commons licenses: <https://creativecommons.org/licenses/>

### Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

LUND UNIVERSITY

PO Box 117  
221 00 Lund  
+46 46-222 00 00

TECHNICAL ADVANCE

Open Access

# Automated image-based assay for evaluation of HIV neutralization and cell-to-cell fusion inhibition

Enas Sheik-Khalil<sup>1,4\*</sup>, Mark-Anthony Bray<sup>2</sup>, Gülsen Özkaya Şahin<sup>1</sup>, Gabriella Scarlatti<sup>3</sup>, Marianne Jansson<sup>1</sup>, Anne E Carpenter<sup>2</sup> and Eva Maria Fenyo<sup>1</sup>

## Abstract

**Background:** Standardized techniques to detect HIV-neutralizing antibody responses are of great importance in the search for an HIV vaccine.

**Methods:** Here, we present a high-throughput, high-content automated plaque reduction (APR) assay based on automated microscopy and image analysis that allows evaluation of neutralization and inhibition of cell-cell fusion within the same assay. Neutralization of virus particles is measured as a reduction in the number of fluorescent plaques, and inhibition of cell-cell fusion as a reduction in plaque area.

**Results:** We found neutralization strength to be a significant factor in the ability of virus to form syncytia. Further, we introduce the inhibitory concentration of plaque area reduction (ICpar) as an additional measure of antiviral activity, i.e. fusion inhibition.

**Conclusions:** We present an automated image based high-throughput, high-content HIV plaque reduction assay. This allows, for the first time, simultaneous evaluation of neutralization and inhibition of cell-cell fusion within the same assay, by quantifying the reduction in number of plaques and mean plaque area, respectively. Inhibition of cell-to-cell fusion requires higher quantities of inhibitory reagent than inhibition of virus neutralization.

**Keywords:** Automated plaque reduction assay (APR assay), Fluorescence, HIV, Neutralization, Fusion inhibition

## Background

The assessment of virus specific antibodies plays a central role in human immunodeficiency virus type 1 (HIV-1) vaccine development [1]. Thus, evaluation of HIV/AIDS preventive vaccines requires the development of methods to assess different properties, including neutralizing capacity, of protective antibody responses. However, no single assay has so far been reported to detect such protective antibodies. Instead, a wide range of HIV-1 neutralization assays and variants thereof have been developed and described in the literature [2,3]. These assays are based on different technologies but they all rely on the principle to measure reduction of virus infectivity in susceptible cells in the presence of inhibitory reagents. Likewise, the plaque reduction assay (PR) is based on virus infectivity and uses

human cell lines (U87.CD4 or GHOST(3)) engineered to express HIV receptors [4,5].

In parallel, major advances in high-throughput fluorescence microscopy and automated, high-content image analysis tools have paved the way for systematic and quantitative study of biological systems [6-10]. Fluorescence-based imaging assays have been applied to large-scale analysis to solve biological problems.

Here, we describe an automated PR assay, including sample preparation, automated image acquisition, and a computational image analysis pipeline using open-source software in order to convert the PR assay for HIV neutralization into a high-throughput, high-content assay. In addition to quantifying neutralization by reduction of plaque number, our high-content assay measures plaque area, permitting studies of cell-cell fusion inhibition. We compare this assay with manual readout and with other neutralization assays using a reference panel of inhibitory reagents, i.e. plasma and monoclonal antibodies. We demonstrate that by the use of image analysis the APR assay is

\* Correspondence: enas.sheik-khalil@med.lu.se

<sup>1</sup>Department of Laboratory Medicine, Lund University, Lund, Sweden

<sup>4</sup>Department of Clinical Microbiology and Immunology, Lund University, Lund, Sweden

Full list of author information is available at the end of the article

converted to a high-throughput and high-content assay, where plaque area is a measure of cell-cell fusion.

## Methods

### Plaque Reduction (PR) assay

Infection assays were done by using HIV-1 isolates (of different subtypes and coreceptor use) and polyclonal inhibitory reagents (eight HIV-positive and one HIV-negative plasma), obtained from the Centre for AIDS Reagents (CFAR) NIBSC, UK, as previously described [3]. We tested virus neutralization in GHOST(3)-CCR5 and -CXCR4 cell lines stably transfected with CD4, chemokine receptors and the Tat-inducible green fluorescence protein (GFP) [4,11]. Three days following exposure of cells to the plasma-virus mixtures, plaque-forming units (PFU) under the fluorescent microscope are counted to calculate neutralization as percentage of plaque reduction (PR) in the sample containing inhibitory reagent:  $[1 - (\text{PFU with inhibitory reagent}/\text{PFU without inhibitory reagent})] \times 100$  [5]. For the manual readout the plaques were counted by eye in separate experiments.

### Automated Plaque Reduction assay (APR assay)


To develop the assay in this study, we adapted the prior protocol for the manual PR assay [4] in 96-well plates and modified the readout by treating cells with Hoechst 33342 for 20 minutes, washing with PBS, and sealing plates with aluminum foil prior to automated image acquisition (Supp. Note 1). For the image acquisition, we used the AxioObserver Z1 with a Zeiss Neofluar Objective 10X/0.3 with the exposure time 200 ms. The inner  $5 \times 3$  images of each well (approx.  $4.108 \text{ mm} \times 5.117 \text{ mm}$ ) were imaged, to be tiled later into a single mosaic image. Assay quantification was performed by developing an APR workflow using the freely available image analysis software CellProfiler (<http://www.cellprofiler.org>) [12,13]. The workflow consists of two pipelines comprised of image processing modules optimized


to identify GHOST(3)-CXCR4 and GHOST(3)-CCR5 cells where HIV infection has activated the GFP marker. The first pipeline tiles the inner  $5 \times 3$  image sites of each well into a single mosaic (approx.  $4.108 \text{ mm} \times 5.117 \text{ mm}$ ) so as not to overestimate by counting plaques that lie on the image edge twice. A secondary purpose for this pipeline is to reduce background fluorescence and illumination heterogeneities present in the images prior to tiling, plaque detection and measurement (Figure 1). The second pipeline is used for plaque identification and measurement of parameters such as total cell and plaque count, plaque area, fluorescence intensity and morphology (Figure 2). In order to assess cell viability, nuclei are also identified and counted based on the DAPI stained images. Syncytia are formed due to merging of multiple cells (Figure 3). Several parameters in this pipeline can be fine-tuned for plaque identification; the effect of altering one such parameter is demonstrated in Figure 4. Detailed instructions on the use of the PR workflow is described in the Additional file 1 and provided online ([http://www.cellprofiler.org/published\\_pipelines.shtml](http://www.cellprofiler.org/published_pipelines.shtml)); other optimization considerations are provided in the module notes that may be viewed when the pipelines are loaded in CellProfiler.

### Details of plaque determination


As is the case for many biological applications, the most challenging bottleneck in configuring an image analysis pipeline is the segmentation, defined as the identification and partitioning of the individual plaques in the image. The IdentifyPrimaryObjects module in the APR image analysis pipeline was adjusted to read foreground/background to match manual reading. The results of the automatic readout and what would be the corresponding manual readout within the same experiment are thus closely similar, if not identical.

Here we describe several key settings contained in the IdentifyPrimaryObjects module in the plaque identification






**Figure 2** Mosaic image of a well (a-c-e) is shown along with outlines (b-d-f) as defined by the borders of plaques and nuclei set by the APR threshold program. All images are taken in the same microscopic field. Plaques (green) and nuclei (blue) are shown as a merged image (a) or plaques alone (c) or all nuclei (e). The green color labeling of the outlines is used for illustrative purposes only.



**Figure 3** A magnified picture of syncytia (green) and nuclei (blue) is shown as a merged image (a) along with the outlines (b). Image of syncytia (c) along with the outlines (d) as well as nuclei inside the syncytia (e) with the outlines (f) clearly show how nuclei cluster inside syncytia. The green color labeling the outlines is used for illustrative purposes only.

pipeline; these are also described in the module notes within the CellProfiler user interface:

- *Choice of automatic thresholding method:* In this context, thresholding refers to the use of intensity values to distinguish the image foreground (i.e., the GFP-expressing plaques) from the background. A number of automatic thresholding methods are provided for use in the module; the thresholding method chosen must not only reliably identify bright distinct plaques but also the smaller, dim single cells in order to be sufficiently sensitive. For the PR assay, the “Robust Background” thresholding method was used, which assumes a Gaussian intensity distribution after trimming the brightest and dimmest 5% of pixel intensities; the threshold is then calculated as the mean of this distribution plus 2 standard deviations.
- *Correction of the threshold value:* If the automatically determined threshold is consistently too high or too low in all images, it can be further refined by adjusting a module setting which multiplies the threshold by a constant value (“threshold correction factor”). Our automatic readout was performed after fine-tuning the threshold correction factor (TCF) on plaque detection in GHOST(3)-CCR5/CXCR4 cells for HIV-1-infected and uninfected cases (as explained in the legend for Figure 4). This selection was made manually by careful review of many plates and pictures, and verified through comparison of uninfected and



HIV-1 infected GHOST(3) cultures. Care is required in correction factor selection since an excessively high value will identify only the brightest plaques (i.e., yield false negatives) and underestimate the plaque area in GFP-positive images, whereas a value that is too low will detect false positives in GFP-negative images (Figure 4). A threshold correction factor of 1.6 was found to be optimal for this assay.

- *Selection of the lower threshold limit:* In instances where the image is GFP-negative (i.e., no plaques), the automatic threshold value may be too low and therefore detects false positives. A lower threshold bound can be set as a precautionary measure by empirically estimating the GFP-negative signal across several images. For the PR assay, the lower threshold bound was set to 0.013.
- *Object exclusion based on plaque size:* The upper and lower bounds for the typical diameter of a GFP-identified plaque can be adjusted to exclude spurious foreground regions, thereby precluding false positives. This size range was set to 4–150 pixels after calculating the mean diameter of a number of individual GHOST(3) cells in brightfield mode (data not shown).

#### PBMC- and pseudovirus- based neutralization assays

The detailed methodologies of the peripheral blood mononuclear cell (PBMC)- and Env (gp160) pseudotyped virus (PSV)-based neutralization assays are available on

the EUROPRISE website ([http://www.europrise.org/neut-net\\_sops.html](http://www.europrise.org/neut-net_sops.html)). In brief, seven laboratories performed the PBMC-based assay, where virus isolates were used with PBMC (isolated from buffy coats of HIV-negative blood donors) as target cells. The PSV-based assay was performed by six different laboratories as a single cycle assay and by one laboratory as a multiple cycle infection assay with engineered cell lines as target cells.


#### Statistics

The non-parametric Spearman rank statistical analysis was used to calculate correlations between findings of the automated and manual plaque reduction assays and neutralization to change in plaque area. For comparison of the three different neutralization assays in relation to virus neutralization sensitivity and plasma neutralization capacity, as well as the mean plaque area of different uninhibited HIV-1 isolates the non-parametric Kruskal Wallis test, with Dunn's post test, was used. Normalized mean plaque area for virus-plasma combinations, at IC<sub>50</sub>, IC<sub>75</sub> and IC<sub>90</sub>, was evaluated according to Friedman's test and Dunn's Post Test.

#### Results

##### Comparison of manual and APR readout

We compared the manual and automated readouts using 72 virus-plasma combinations, including eight combinations with HIV-negative plasma (Figure 5). In 46 cases (64%), the manual and automatic readouts of



50% inhibitory concentration (IC50) were within two-fold of each other and in 12 cases (17%) the difference was within a 2- to 3-fold range. This is an insignificant degree of variation in accordance with the accepted convention used in clinical virology (e.g., if serial 2-fold dilutions of antibodies are used). In the remaining 14 virus-plasma combinations (19%), variation of IC50 was more than 3-fold between manual and automatic readouts. Further examination of this latter group revealed that in 11 out of 14 combinations, the automatic readout was more sensitive than the manual readout in detecting neutralization (denoted as triangles above the diagonal line in Figure 5). These 14 points were not the result of an image analysis artifact, since no false positive background was detected with the negative plasma and the manual and automatic readout of other inhibitory reagent-virus combinations run on the same plate and day were in close agreement. Taken together, the APR assay detected neutralization similarly, but with generally increased sensitivity, as compared to the manual PR readout.

#### Comparison of APR assay with other HIV-1 neutralization assays


The APR assay has been developed within the framework of an international network for comparison of HIV

neutralization assays [3]. Comparisons on the IC50 level with other virus infection assays, including the PBMC and pseudovirus (PSV) assays using plasma and monoclonal antibodies, showed that sensitivities were dependent on both virus and plasma (Figure 6a and b). No statistical differences were found when comparing results of the APR and the PBMC-based assays when considering either virus neutralization sensitivity or plasma neutralization capacity. When comparing the APR and the PSV assays, virus neutralization sensitivity was statistically similar for seven out of eight viruses (Figure 6a); neutralization of 92UG024 was detected with higher sensitivity with the PSV assay as compared to both the APR assay ( $p < 0.05$ ) and the PBMC assay ( $p < 0.001$ ) (Figure 6a). For the neutralization capacity of plasma, results generated from the APR and the PSV assay were not significantly different with six out of eight plasma tested (Figure 6b). The exceptions were plasma ARP521 and ARP522, which displayed higher neutralization titers in the PSV assay compared with the APR assay ( $p < 0.01$ ). We noted that it was particularly the use of ARP521 and ARP522 in combination with the 92UG024 and SF162 viruses that influenced the results. Overall, the sensitivity of the automatic PR assay was in the range of the other assays.

#### High-content readout by the APR assay allows analysis of cell-cell fusion inhibition

We next evaluated the capacity of the APR assay to quantify the size of the plaque area, as a measure of cell-cell fusion. Changes in mean plaque area were evaluated in single virus-inhibitory reagent combinations. Results showed that quantification of plaque area was possible. Analysis of the relationship between neutralization level and plaque area across virus-inhibitory reagent combinations where IC50, IC75 and IC90 was achieved, revealed that the mean plaque area was significantly reduced at 90% inhibitory concentration (IC90) but not at IC50 (Figure 7), indicating that the level of neutralization seems to be important for inhibition of virus-mediated cell-cell fusion. Furthermore, the decrease in plaque area was statistically significant only when neutralization reached IC90 with plasma dilution exceeding 1:50 or an antibody concentration above 6  $\mu\text{g}/\text{mL}$  (for TriMab). This was the case for four inhibitory reagent-virus combinations (Figure 8a, c, e and Additional file 1: Table S1).

Fourteen combinations that reached IC90 with a plasma dilution lower than 1:50 and 11 combinations that reached IC50 showed a trend towards decreased plaque area but could not be statistically confirmed (exemplified in Figure 8b). Apparently, the steep fall in neutralizing activity upon dilution provided too few points for curve fitting. Twelve other inhibitory reagent-virus combinations that showed neutralization did not display reduction in mean plaque area (exemplified in Figure 8d). As




expected, those inhibitory reagents lacking neutralizing activity against a particular virus did not affect the plaque area (e.g., Figure 8f). We did not identify a particular reagent capable of reducing plaque area of all viruses.

For quantitative analysis of plaque reduction we introduced a new nomenclature, ICpar (inhibitory concentration

for plaque area reduction). ICpar indicates the concentration at which the antibody causes a decrease in plaque area, e.g., ICpar50 is a 50% reduction in plaque area. IC90 and ICpar50 values were similar for most virus-antibody combinations (Figure 8 and Additional file 1: Table S1) indicating that inhibition of cell-to-cell





fusion requires higher quantities of inhibitory reagent than inhibition of virus cell entry and replication.

#### Virus-induced cell-cell fusion characteristics based on plaque area readout

We next analysed the size of the plaque area in relation to the different virus isolates. The mean plaque area of each virus yielded a characteristic size distribution (Figure 9), regardless of virus titration (data not shown). However, neither coreceptor use nor subtype of HIV-1 correlated to plaque area, as both X4 and R5 viruses and subtype B and C viruses were found across the size distribution. It is interesting to note that the 92UG024 virus, yielding relatively small plaques, was used in five of the 11 cases where automatic readout was more sensitive, suggesting that the small plaques may be more difficult to score by eye.

#### Discussion


Here we describe a novel image-based methodology for assaying HIV neutralization in an automated high-content manner. Our high-content assay allows, for the first time, evaluation of both HIV neutralization and inhibition of cell-cell fusion within the same assay. This is achieved by quantifying the reduction in number of plaques and mean plaque area, respectively. The image analysis pipeline for the APR assay in GHOST(3) cells is based on the freely available CellProfiler software [12] and has now been

optimized and adapted for automated reading. Automation offers many advantages: it is higher throughput, standardized, and inexpensive compared both to the manual PR assay and the classic virus infection assay performed in peripheral blood mononuclear cells (PBMC). Automated image analysis increases the objectivity of the plaque counting demonstrated by the very low intra-well variation among triplicate wells (data not shown) as well as low background in the negative controls.

A striking feature of the image-based approach is that it allows extraction of additional phenotypic features of viruses, including cell-cell fusion capacity. We observed differences between the eight HIV-1 isolates used in the present study. In fact, based on statistically significant differences in mean plaque area, viruses could be divided into two groups yielding large or small plaques. Large plaques may result from fusion of a higher number of cells than small plaques. It has been suggested that virus ability to mediate cell-cell fusion, i.e. syncytia, depends on the strength of the interaction of viral envelope protein with CD4 and coreceptors [14,15]. In addition, Env clustering and mobility in the cell membrane may influence the outcome of syncytia formation [16].

Our results show that a higher concentration of inhibitory reagent was needed to get a reduction in plaque area than that needed for neutralization. This was previously proposed by Yee et al. [17] and given the explanation that the interaction of the envelope glycoproteins gp120/gp41 (Env) with cell membrane CD4 may be different during cell-cell fusion than during virus-cell membrane fusion [18]. It is plausible that the molecular organization and surface density of gp120/gp41 may be different in Env-expressing cells and HIV-1 virions. Indeed, Purtscher et al. [19] proposed, similarly to what we show, that elevated concentrations of antibody are necessary to inhibit fusion between infected and target cells, and suggested this to be due to higher levels of gp120/gp41 expressed on the surface of infected cells as compared to the viral envelope. Interestingly, it was recently shown, in an HIV-1-infected humanized mouse model, that infected T cells form contacts with uninfected cells, and when the frequency of these contacts was reduced, plasma viremia was significantly decreased, strongly suggesting a role for cell-cell contacts in systemic viral spread [20]. Thus, it is conceivable that cell-cell fusion inhibition capacity of an antibody has a role in mitigating pathogenesis and may also be required for an effective HIV vaccine.

Antibody assessment plays a central role in HIV-1 vaccine development where, analogous to other virus infections, virus neutralization is considered particularly important. Accordingly, international comparisons of a wide range of HIV-1 neutralization assays have been performed and showed that no assay alone detects




**Figure 8 Relationship between neutralization and plaque area.** —, mean plaque area ( $\mu\text{m}$ , y axis on the right) indicated with a solid line; - - - - - , neutralization (NAC%, y axis on the left) indicated with a broken line in each panel and ICpar50 values are indicated with vertical dotted lines in panel **a**, **b** and **c**. The plaque area without addition of inhibitory reagent (virus only) is indicated by a horizontal line on the y axis on the right. Virus-plasma combinations: **(a)** ARP516-SF162; **(b)** ARP517-QH0692; **(c)** TriMab-SF162; **(d)** TriMab-QH0692; **(e)** ARP517-MN(P); **(f)** ARP516-MN(P). R and p values are given for the correlation of neutralization and plaque area according to Spearman rank.

neutralization over the entire spectrum of virus-reagent combinations [2,21]. The APR assay has also been standardized and compared with other HIV neutralization assays within the framework of an international collaboration, Neutnet [2,3]. As with the other assays, the sensitivity of our assay was dependent on both the neutralizing reagent and the virus. Thus the APR assay can be considered an information-rich alternative to the PBMC and PSV assays.

## Conclusions

Here we report on a novel image-based automated plaque-reduction assay where both HIV neutralization and inhibition of cell-cell fusion can be analyzed, for the first time within the boundaries of the same assay format. This high-content assay may be used as a tool for evaluation of multiple antibody effector functions, by ways of quantifying the reduction in number of plaques and mean plaque area, respectively. The image analysis



**Figure 9 HIV-1 isolates display different characteristic plaque size. (a)** Mean plaque area of uninhibited HIV-1 isolates with subtype and coreceptor use, indicated in parentheses. Each dot represents the mean plaque area per/well given in microns (Y axis). Horizontal bars indicate the mean of four to nine experiments run in triplicate wells. Statistically significant differences according to Kruskal-Wallis test and Dunn's Post test. \* < 0.05; \*\*\* < 0.001. **(b)** MN(P) exhibit larger plaques (left) while 92UG024 exhibit smaller plaques (right) regardless of virus titer.

platform described herein can be further developed with the potential to study additional features of antibody-virus-cell interactions, which may prove important in antibody-based HIV vaccine design.

### Additional file

**Additional file 1: Table S1.** High-throughput, automated, image-based assay for HIV neutralization by plaque reduction.

### Competing interests

With regard to financial competing interests:

In the past five years we have not received reimbursements, fees, funding, or salary from an organization that may in any way gain or lose financially from the publication of this manuscript, either now or in the future. The article-processing charge will partly be financed by Lund University.

We do not hold any stocks or shares in an organization that may in any way gain or lose financially from the publication of this manuscript. We do not hold or are currently applying for any patents relating to the content of this manuscript. No reimbursements, fees, funding, or salary were received from an organization that holds or has applied for patents relating to the content of the manuscript.

With regard to non-financial competing interests:

There are no non-financial competing interests (political, personal, religious, ideological, academic, intellectual, commercial or any other) to declare in relation to this manuscript.

### Authors' contribution

ESK, MB, GÖS, GS, MJ, AC and EMF. ESK has developed the reading of microplates on an automatic reading platform, participated in development of image analysis pipelines, and drafted the manuscript. MB and AC developed the image analysis pipelines adapted for evaluation of HIV neutralization assay by plaque reduction and participated in writing the manuscript. ESK also performed the neutralization assays together with GÖS. MJ was involved in technical supervision of neutralization assays and in analysis of manual and automatic reading results. GS was responsible for coordinating the international comparative study of HIV neutralization assays. EMF conceived of the study, and participated in its design and coordination and helped to draft the manuscript. All authors read and approved the final manuscript.

### Acknowledgments

MAB and AEC were supported by NIH R01 GM089652.

Grants were received from the Swedish Research Council, the Swedish International Development Cooperation Agency/Department for Research Cooperation (SIDA/SAREC), the Crafoord Foundation and the European Community: EUROPRISE-Network of Excellence grant number LSHT-CT-2006-037611 and NGIN grant number 201433.

#### Author details

<sup>1</sup>Department of Laboratory Medicine, Lund University, Lund, Sweden. <sup>2</sup>Broad Institute of Harvard and MIT, Imaging Platform, Cambridge, MA, USA. <sup>3</sup>Viral Evolution and Transmission Unit, San Raffaele Scientific Institute, Milan, Italy. <sup>4</sup>Department of Clinical Microbiology and Immunology, Lund University, Lund, Sweden.

Received: 25 April 2014 Accepted: 18 August 2014

Published: 30 August 2014

#### References

- McCoy LE, Weiss RA: Neutralizing antibodies to HIV-1 induced by immunization. *J Exp Med* 2013, **210**(2):209–223.
- Fenyo EM, Heath A, Dispinseri S, Holmes H, Lusso P, Zolla-Pazner S, Donners H, Heyndrickx L, Alcamì J, Bongertz V, Jassoy C, Malnati M, Montefiori D, Moog C, Morris L, Osmanov S, Polonis V, Sattentau Q, Schuitemaker H, Sutthent R, Wrin T, Scarlatti G: International network for comparison of HIV neutralization assays: the NeutNet report. *PLoS One* 2009, **4**(2):e4505.
- Heyndrickx L, Heath A, Sheik-Khalil E, Alcamì J, Bongertz V, Jansson M, Malnati M, Montefiori D, Moog C, Morris L, Osmanov S, Polonis V, Ramaswamy M, Sattentau Q, Tolazzi M, Schuitemaker H, Willems B, Wrin T, Fenyo EM, Scarlatti G: International network for comparison of HIV neutralization assays: the NeutNet report II. *PLoS One* 2012, **7**(5):e36438.
- Lauren A, Thorstensson R, Fenyo EM: Comparative studies on mucosal and intravenous transmission of simian immunodeficiency virus (SIVsm): the kinetics of evolution to neutralization resistance are related to progression rate of disease. *J Gen Virol* 2006, **87**(Pt 3):595–606.
- Shi Y, Albert J, Francis G, Holmes H, Fenyo EM: A new cell line-based neutralization assay for primary HIV type 1 isolates. *AIDS Res Hum Retroviruses* 2002, **18**(13):957–967.
- Ljosa V, Carpenter AE: Introduction to the quantitative analysis of two-dimensional fluorescence microscopy images for cell-based screening. *PLoS Comput Biol* 2009, **5**(12):e1000603.
- Pegoraro G, Bavari S, Panchal RG: Shedding light on filovirus infection with high-content imaging. *Viruses* 2012, **4**(8):1354–1371.
- Pepperkok R, Ellenberg J: High-throughput fluorescence microscopy for systems biology. *Nat Rev Mol Cell Biol* 2006, **7**(9):690–696.
- Starkuviene V, Pepperkok R: The potential of high-content high-throughput microscopy in drug discovery. *Br J Pharmacol* 2007, **152**(1):62–71.
- Rose PP, Hanna SL, Spiridigliozzi A, Wannissorn N, Beiting DP, Ross SR, Hardy RW, Bambina SA, Heise MT, Cherry S: Natural resistance-associated macrophage protein is a cellular receptor for sindbis virus in both insect and mammalian hosts. *Cell Host Microbe* 2011, **10**(2):97–104.
- Morner A, Bjorndal A, Albert J, Kewalramani VN, Littman DR, Inoue R, Thorstensson R, Fenyo EM, Bjorling E: Primary human immunodeficiency virus type 2 (HIV-2) isolates, like HIV-1 isolates, frequently use CCR5 but show promiscuity in coreceptor usage. *J Virol* 1999, **73**(3):2343–2349.
- Carpenter AE, Jones TR, Lamprecht MR, Clarke C, Kang IH, Friman O, Guertin DA, Chang JH, Lindquist RA, Moffat J, Golland P, Sabatini DM: CellProfiler: image analysis software for identifying and quantifying cell phenotypes. *Genome Biol* 2006, **7**(10):R100.
- Kamentsky L, Jones TR, Fraser A, Bray MA, Logan DJ, Madden KL, Ljosa V, Rueden C, Eliceiri KW, Carpenter AE: Improved structure, function and compatibility for CellProfiler: modular high-throughput image analysis software. *Bioinformatics* 2011, **27**(8):1179–1180.
- Watkins BA, Crowley R, Davis AE, Louie AT, Reitz MS Jr: Syncytium formation induced by human immunodeficiency virus type 1 isolates correlates with affinity for CD4. *J Gen Virol* 1997, **78**(Pt 10):2513–2522.
- Shiva Naresh Mulampaka NMD: Estimating the threshold surface density of Gp120-CCR5 complexes necessary for HIV-1 envelope-mediated cell-cell fusion. *PLoS One* 2011, **6**(5):e19941.
- Roy NH CJ, Lambelè M, Thali M: Clustering and mobility of HIV-1 Env at viral assembly predict its propensity to induce cell-cell fusion. *J Virol* 2013, **87**(13):7516–7525.
- Yee M, Konopka K, Balzarini J, Duzgunes N: Inhibition of HIV-1 Env-mediated cell-cell fusion by lectins, peptide T-20, and neutralizing antibodies. *Open Virol J* 2011, **5**:44–51.
- Konopka K, Pretzer E, Celada F, Duzgunes N: A monoclonal antibody to the gp120-CD4 complex has differential effect on HIV-induced syncytium formation and viral infectivity. *J Gen Virol* 1995, **76**(Pt 3):669–679.
- Purtscher M, Trkola A, Gruber G, Buchacher A, Predl R, Steindl F, Tauer C, Berger R, Barrett N, Jungbauer A, Katinger H: A broadly neutralizing human monoclonal antibody against gp41 of human immunodeficiency virus type 1. *AIDS Res Hum Retroviruses* 1994, **10**(12):1651–1658.
- Murooka TT, Deruaz M, Marangoni F, Vrbanac VD, Seung E, von Andrian UH, Tager AM, Luster AD, Mempel TR: HIV-infected T cells are migratory vehicles for viral dissemination. *Nature* 2012, **490**(7419):283–287.
- Polonis VR, Brown BK, Rosa Borges A, Zolla-Pazner S, Dimitrov DS, Zhang MY, Barnett SW, Ruprecht RM, Scarlatti G, Fenyo EM, Montefiori DC, McCutchan FE, Michael NL: Recent advances in the characterization of HIV-1 neutralization assays for standardized evaluation of the antibody response to infection and vaccination. *Virology* 2008, **375**(2):315–320.

doi:10.1186/1471-2334-14-472

Cite this article as: Sheik-Khalil et al.: Automated image-based assay for evaluation of HIV neutralization and cell-to-cell fusion inhibition. *BMC Infectious Diseases* 2014 **14**:472.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at  
www.biomedcentral.com/submit

